Lerodalcibep reduces LDL cholesterol by over 50% in high-risk patients - report from ACC2024

Professor Eric Quinton Klug shared his insights on the LIBerate-HR trial. Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo. In addition, 90% of patients treated with lerodalcibep, versus 16% of those on placebo, attained the newer, more stringent guideline-recommended LDL targets set by the American College of Cardiology and other expert organizations. Video: https://medicaldigest.org/scientific-contents/interview:lerodalcibep-reduces-ldl-cholesterol-over-50-high-risk-patients